Samer Al Hadidi, MD,MS,FACP (@HadidiSamer) ranks #2 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 97 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MajesTEC-3, MajesTEC-9, EXCALIBER-RRMM. CMS Open Payments lists $2,159 in 2025 general payments.
At a Glance
- 118 posts naming a trial since ASH 2025
- 33 trials discussed by name
- Multiple Myeloma: US #2, Global #2 · 97 physicians engaged
- Leading physician voice: #1 of 9 physicians on CARTITUDE-4; #1 of 6 physicians on inMMyCAR
- CMS Open Payments lists $2,159 in 2025 general payments.
This Month
What Samer Al Hadidi, MD,MS,FACP has posted in the last 30 days. Updated November 11, 2026.
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory) ➡️n=838; median FU: 13.4 mo ➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55). 🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs) Time limited therapy with dual targeting in pts after anti-CD38/len failure
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 3⃣iMMagine-1: Anito-cel ➡️registrational phase II, RRMM 4th line or later ➡️ n=117; median FU 18 mo ➡️ORR 96%, CR/sCR 75%, MRD negative at 10⁻⁵ 95%. 24-mo PFS 58% and 24-mo OS 84% 🛑CRS 86%, almost all grade 1–2 (one grade 5). ICANS 8% (one grade 3). Grade ≥3 infections only 9% ➡️No parkinsonism, cranial nerve palsy, GBS, IEC-enterocolitis or secondary T-cell malignancy Short follow up and relapses already occurring in ~ half of patients indicating likely lower efficacy than Cilta Cel though with no safety signal with short follow up The ASH 2026 iMMagine-1 abstract uses a January 5, 2026 cutoff, only about 3 months after the ASH 2025 cutoff
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 4⃣EXCALIBER-RRMM: Iberdomide-Dd vs DVd ➡️ Phase III RRMM after 1–2 prior lines, not anti-CD38- or bortezomib refractory ➡️median follow-up 15.7 mo, MRD-negative CR was 41% vs 21% (OR 2.75). MRD-negative CR lasting ≥12 months was 18.8% vs 6.6%. PFS press release: 42 months with Iberdomide-Dd vs 20 months with DVd (HR 0.49) 🛑Grade 3/4 neutropenia very high (84% vs 11%), Grade 3/4 infections were 39% vs 22%. Good to see improvement of PFS, however BCMA therapies should be used prior given OS benefit
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 7⃣BMS-986453: Dual BCMA×GPRC5D CAR-T ➡️ phase I, RRMM after ≥3 prior lines (median 4), 60% prior BCMA therapy, 17% prior BCMA and GPRC5D; ➡️n=58; median FU ~ 1 yr ➡️Efficacy at 75–150M dose: ORR 94% (CR 71%), and 89% even after prior BCMA therapy. In naïve patients: ORR 100%, CR 88%, MRD-negative at 10⁻⁶ 100%, 12-mo PFS 93% (62% overall). 🛑CRS 78% (one grade 5, at 300M), ICANS 3%, infections 52% (21% grade ≥3). GPRC5D on-target/off-tumor effects in 50% (nails 36%, oral 34%, skin 19%) Nice to see data on dual targeting CAR-T
Who Amplifies Samer Al Hadidi, MD,MS,FACP
Physicians who reposted Samer Al Hadidi, MD,MS,FACP’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #2 | #2 | 94/100 | 97 | 247 | Full ranking |
Trials Samer Al Hadidi, MD,MS,FACP Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MajesTEC-3 | 19 | #3 of 15 | Sep 24, 2026 |
| MajesTEC-9 | 14 | #3 of 16 | May 30, 2026 |
| EXCALIBER-RRMM | 9 | #3 of 13 | Nov 11, 2026 |
| MonumenTAL-3 | 8 | #3 of 9 | Jun 13, 2026 |
| ETENTAMIG | 5 | — | Dec 7, 2025 |
| RedirecTT-1 | 5 | #9 of 10 | Dec 7, 2025 |
| TECLILLE | 5 | — | Dec 6, 2025 |
| CERVINO | 4 | #3 of 11 | Sep 25, 2026 |
| inMMyCAR | 4 | #1 of 6 | May 31, 2026 |
| SUCCESSOR-2 | 4 | #3 of 15 | May 29, 2026 |
| BENEFIT | 4 | — | Dec 7, 2025 |
| TRIlogy-1 | 3 | #1 of 5 | Sep 24, 2026 |
| STEM | 3 | — | Dec 7, 2025 |
| CAMMA-3 | 3 | — | Dec 7, 2025 |
| IMMUNOPLANT | 3 | — | Dec 6, 2025 |
| MonumenTAL-6 | 2 | #1 of 4 | Nov 11, 2026 |
| iMMagine-1 | 2 | #1 of 3 | Nov 11, 2026 |
| UK-MRA RADAR | 2 | #1 of 3 | Sep 24, 2026 |
| LINKER-MM4 | 2 | — | Dec 7, 2025 |
| GMMG-CONCEPT | 2 | — | Dec 7, 2025 |
| CARTITUDE-4 | 2 | #1 of 9 | Dec 6, 2025 |
| MagnetisMM-30 | 2 | — | Dec 6, 2025 |
| BMS-986453 | 1 | #3 of 3 | Nov 11, 2026 |
| PERSEUS | 1 | #3 of 10 | Sep 25, 2026 |
| anito-cel | 1 | #2 of 7 | Sep 24, 2026 |
| SeaLAND | 1 | — | Sep 24, 2026 |
| ImmunoPRISM | 1 | — | Sep 13, 2026 |
| QUINTESSENTIAL | 1 | — | Sep 9, 2026 |
| CEPHEUS | 1 | #3 of 8 | May 31, 2026 |
| DREAMM-7 | 1 | — | Dec 7, 2025 |
| AURIGA | 1 | — | Dec 6, 2025 |
| CARTITUDE-1 | 1 | — | Dec 6, 2025 |
| LimiTec | 1 | — | Nov 10, 2025 |
Samer Al Hadidi, MD,MS,FACP on MajesTEC-3
#IMS26 #mmsm Oral MajesTEC-3 post hoc analysis @End_myeloma ➡️ In Tec-Dara, progressions became uncommon after 6 months, with an reduction in disease progression (sHR, 0.10), which is the leading cause of mortality in RRMM https://t.co/jctyzj62b3
#IMS26 #mmsm Oral MajesTEC-3 post hoc analysis @End_myeloma ➡️Tec-Dara reduced the risk of death by 78% versus DPd/DVd after 10 months with similar early deaths Better AEs management will help further mitigate higher risk of infection early on Moving forward this should change to time limited therapy given excellent results and depth of response
#mmsm #EHA26 MajesTEC-3 high risk post hoc analysis @RahulBanerjeeMD Tec-Dara worked well in patients with 2HRCA or more as well as functionally high risk Really good results in hard to treat patients https://t.co/A2zYezcsXA
Samer Al Hadidi, MD,MS,FACP on MajesTEC-9
#ASCO26 #mmsm Some easy summary data for MajesTEC-9, really nice results and summary of adverse events https://t.co/S9nYxJ9RM6
#ASCO26 #mmsm Oral sessions myeloma MajesTEC-9 KD was given in 69% of patients in control arm (~205 patients) Steroids were dropped early in the treatment course Patients characteristics below https://t.co/j0HQbyOoP8
#ASCO26 #mmsm Oral sessions myeloma MajesTEC-9 Still ~21% released on Tec but much lower than comparator arm Improved PFS and responses including MRD negativity https://t.co/yMK4FSL9fB
Samer Al Hadidi, MD,MS,FACP on EXCALIBER-RRMM
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 4⃣EXCALIBER-RRMM: Iberdomide-Dd vs DVd ➡️ Phase III RRMM after 1–2 prior lines, not anti-CD38- or bortezomib refractory ➡️median follow-up 15.7 mo, MRD-negative CR was 41% vs 21% (OR 2.75). MRD-negative CR lasting ≥12 months was 18.8% vs 6.6%. PFS press release: 42 months with Iberdomide-Dd vs 20 months with DVd (HR 0.49) 🛑Grade 3/4 neutropenia very high (84% vs 11%), Grade 3/4 infections were 39% vs 22%. Good to see improvement of PFS, however BCMA therapies should be used prior given OS benefit
PFS benefit reported with Iber-Dara-Dex vs DVd with median PFS of 42 months vs 20 months [HR:0.49, p<0.000001] #mmsm Hope to see full results soon of EXCALIBER-RRMM ➡️ https://t.co/bTQjpedo74
#IMS26 #mmsm Plenary EXCALIBER-RRMM with also publication 🧵 Important initial observations Study schema - note Len refractory was 1 out of 3 in IberDd ( 2 out of 3 were not refractory to Len) Dara-VD (control arm) was per CASTOR trial (i.e: the arms are asymmetric) https://t.co/HkcW5Sw82l
Samer Al Hadidi, MD,MS,FACP on MonumenTAL-3
#mmsm #EHA26 MonumenTAL-3 Published @NEJM 🛑Ataxia/balance disorders: Tal-DP 15%, Tal-D 12%, DPd 0.4%. 🛑Onset is late: median ~292–326 days, increasing from cycle 7 onward (11% Tal-DP, 10% Tal-D)-Led to talquetamab discontinuation: 5% (Tal-DP) vs 2% (Tal-D) The major issue https://t.co/U9WE9EXgcZ
#mmsm #EHA26 MonumenTAL-3 Published @NEJM 🛑Fatal AEs: Tal-DP 2% (n=5), Tal-D 4% (n=11),DPd 5% (n=13) 🛑 Grade 3/4 neutropenia: Tal-DP 76%, Tal-D 29%, DPd 86% (questionable benefit of pomalidomide addition with significant increased myelosuppression) 🛑Grade 3/4 infections: 38% https://t.co/AiGpycKUp3
#mmsm #EHA26 MonumenTAL-3 Published @NEJM ➡️ https://t.co/tRTOmHky2O ✅RCT, phase 3: Tal-DP vs Tal-D vs DPd ✅ Treatment was until progression or intolerance (not time-limited) ✅ Early relapse ≥1 prior line including lenalidomide + PI ( no anti-CD38 refractory) ✅allowed https://t.co/R8IeEr5FpI
Samer Al Hadidi, MD,MS,FACP on ETENTAMIG
#ASH25 #mmsm @ASH_hematology Oral-amyloidosis Etentamig @rajshekharucms R/R AL amyloidosis, patients characteristics https://t.co/1PKqc7cH02
#ASH25 #mmsm @ASH_hematology Oral-amyloidosis Etentamig @rajshekharucms Excellent early responses including hematological and organ responses ( BCMA targeting is exciting in AL amyloidosis) https://t.co/OqKsNBJ5Li
#ASH25 #mmsm @ASH_hematology Oral-amyloidosis Etentamig @rajshekharucms Promising therapy for amyloidosis, relatively lower infection likely related to lower reporting https://t.co/09OIX7tf5o
Samer Al Hadidi, MD,MS,FACP on RedirecTT-1
#ASH25 #mmsm @ASH_hematology Oral- myeloma -RedirecTT-1 study @szusmani Imp study in EMD disease in myeloma https://t.co/dzyGH9oHFG
#ASH25 #mmsm @ASH_hematology Oral- myeloma -RedirecTT-1 study @szusmani 11 patients had grade 5 (fatal) adverse events, with 7 being non-responders dual targeting approach (GPRC5D + BCMA) is a promising new standard of care for triple-class exposed R/R MM with EMD though with https://t.co/n2QzXPin1N
#ASH25 #mmsm @ASH_hematology Oral- myeloma -RedirecTT-1 study @szusmani Published @NEJM https://t.co/lR0eEi0ROZ
Samer Al Hadidi, MD,MS,FACP on TECLILLE
#ASH25 #mmsm @ASH_hematology Oral myeloma- IFM2021-01 teclille trial teclistamab+daratumumab in elderly patients with NDMM not transplant eligible Very exciting study Upfront use of BCMA combination https://t.co/1XcYj23Ijj
#ASH25 #mmsm @ASH_hematology Oral myeloma- IFM2021-01 teclille trial teclistamab+daratumumab in elderly patients with NDMM not transplant eligible This deserves a tweet alone, a flat line, short follow up but really great early results ⭐️⭐️⭐️⭐️⭐️ https://t.co/NLnSldE32m
#ASH25 #mmsm @ASH_hematology Oral myeloma- IFM2021-01 teclille trial teclistamab+daratumumab in elderly patients with NDMM not transplant eligible <1 year follow up all valuable MRD were negative at 100% Great results https://t.co/k6hU6trTUw
Samer Al Hadidi, MD,MS,FACP on CERVINO
#IMS26 #mmsm Plenary CERVINO Etentamig: IV, given less often and with one SUD given prior to full dose Patients can stop therapy after 2 years The comparator arm is: Kd, SVd and EloPd (not used in the US nowadays) https://t.co/myXWsG2nnI
#IMS26 #mmsm Plenary CERVINO Adverse events seems favorable with lower incidence of CRS (0% with Toci) Lower risk of infection (less dosing is a plus) Overall there will be SC option available in the future More studies will be done with other comparative arms and in AL https://t.co/dy3qiONAKE
#IMS26 #mmsm Plenary CERVINO Patient characteristics summarized as well as disposition Better ORR and better PFS with ~ 1 year follow up https://t.co/xzWg1Mgl5s
Samer Al Hadidi, MD,MS,FACP’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#ASH25 #mmsm @ASH_hematology Treatment Refinement in Multiple Myeloma @SLentzsch Reasons why CAR-T should be positioned before BsAbs https://t.co/cYiU44RR7f
An important work by @GomezDLeonMD #mmsm #ASH25 @ASH_hematology #ASHKudos Low-dose teclistamab (0.7mg/kg) in outpatient R/R myeloma ▶️impressive 91% ORR (65% ≥CR) ▶️12-mo PFS 71%, OS 81% ▶️ 65% CRS (mostly grade 1) ▶️infections common but no tx-related deaths Half the dose https://t.co/xmzzaPGE7t
#IMS26 #mmsm @SurbhiSidanaMD Management of rare AE associated with CAR-T in myeloma https://t.co/VAiw0VwE2Q
6️⃣What is the efficacy ? This is a secondary goal (the most important Q in this study was safety) ✅ median follow up: 15 months ✅ MRD negativity 10−6 by 2 months: 100% Deep responses , short follow up to assess durability Bottom line For asymptomatic condition with a https://t.co/KVUZsVT2gA
#ASH25 #mmsm @ASH_hematology Friday satellite program Summary table to induction regiments in transplant eligible myeloma patients https://t.co/GYjQEQ3RAJ
Industry Payments
CMS Open Payments · 2025 general payments
$2,159 across 6 payments